Summary In this study, 44 primary or metastatic human ovarian tumours were tested for allelic deletions on the short arm of chromosome 11. Analysis of 12 polymorphic loci by Southern blotting evidenced loss of heterozygosity (LOH) in at least one locus in 41% of cases. Moreover, two hot spots of deletions were tentatively mapped on lIpl3 and lp1 5.5. Our results demonstrated that LOH at lIp is a common event in ovarian carcinomas and were indicative of the possible existence in lip of two oncosuppressor genes involved in ovarian carcinogenesis. The similarity observed with lIp allelic losses in Wilms tumours, clustered in lIpl3 and lp1 5.5 too, suggests that deletion and possibly inactivation of the same growth regulatory genes (WT genes) could also contribute to development of the malignant phenotype in ovarian carcinomas. Finally, a statistically significant association (P = 0.005) between I lp deletions and hepatic involvement was suggested by the analysis of distribution of lIp LOH relative to different clinical and pathological parameters of the tumour patients.
Ovarian cancer is the major cause of death in individuals with gynaecologic tumours. Relatively little is known about the molecular events associated with the development and subsequent progression and metastasis of epithelial ovarian tumours.
Genetic changes found in ovarian cancer include activation of oncogenes (van't Veer et al., 1988; Zhou et al., 1988; Boltz et al., 1989; Slamon et al., 1989; Enomoto et al., 1991) and allelic losses, reflecting a possible inactivation of tumour suppressor genes. In particular, loss of heterozygosity (LOH) at the short arm of chromosome 11 was reported as a very common event (Ehlen & Dubeau, 1990; Lee et al., 1990; Viel et al., 1991) , but also frequent allelic losses of genes mapped on chromosomes 3, 6, 13 and 17 were described (Eccles et al., 1990; Ehlen & Dubeau, 1990; Lee et al., 1990; Russel et al., 1990; Li et al., 1991; Okamoto et al., 1991) .
Tumour suppressor genes on chromosome Ilp seem to be involved in several other malignancies, including bladder (Fearon et al., 1985) , breast (Ali et al., 1987; Mackay et al., 1988) , lung (Weston et al., 1989; Ludwig et al., 1991) and adrenocortical (Henry et al., 1989) carcinomas; testicular cancers (Lothe et al., 1989) ; Wilms tumours (Reeve et al., 1989; Wadey et al., 1990) ; hepatoblastomas (Koufos et al., 1985) and Rhabdomyosarcomas (Scrable et al., 1987) . Allelic losses on lip, sometimes concurrent with LOH at a number of different chromosomes, may affect certain unknown genes, providing selective growth advantages and leading to a further destabilisation of the genome (Devilee et al., 1991) . In a subset of Wilms tumours the oncosuppressor gene involved in the LOH at lip has been identified: losses or functional inactivations of the WT-1 gene, mapping on lIpl3, are associated with both genetic predisposition (in hereditary cases) and tumourigenesis (Haber et al., 1990; Gessler et al., 1990; Pelletier et al., 1991a; Pelletier et al., 1991b) . However, linkage analysis and deletion mapping studies on lip suggested the presence of another critical Wilms tumour gene on 11p15.5 (Koufos et al., 1989; Reeve et al., 1989; Wadey et al., 1990) , but the putative WT-2 gene has not yet been identified.
At the present it is unknown if WT genes are growth regulatory genes also involved in the aetiology of other tumours displaying Ilp LOH. The only report suggesting WT-1 function abrogation in non Wilms tumour malignancies, described WT-1 mutation in a juvenile granulosa cell tumour from a Denys Drash individual (Pelletier et al., 1991a) .
In the present study we All patients studied and related major clinicopathological data are listed in Table I. Southern blot analysis and probes High molecular weight DNA was prepared from tumour and normal specimens by standard methods (Sambrook et al., 1989) . DNA restriction, electrophoresis in agarose gel, hybridisation and washing conditions were as previously described (Viel et al., 1990) . The DNA probes used in this study are listed in Table II Ha-rasl 1 lpl5.5 p344 (Pulciani et al., 1982) BamHI (6.6) BamHI (7.8-7.6-7.2-6.7-6.6) IGF-2 1 lpl5.5 phins3l1 (Xiang et al., 1987) EcoRI (8.6) BamHI (2.2-1.2) Insulin llpl5.5 phins31o (Bell et al., 1981) BamHI (0.88) TaqI (7.4-6.1-5.4-4.6) Dl S12
1 IpI5.5 pADJ762 (Barker et al., 1984) EcoRI ( pJl9.4 (Housman et al., 1985) BamHI-EcoRI (2.1) BamHI (21-13) P-FSH I lpl3 pSHc-7 (Watkins et al., 1987) HinclI-SacI (0.5) HindlIl (14-12) DllS16 llpl3 P32-1 (Feder et al., 1985) EcoRI (8.9) MspI (11-7.6+6+4-6+4+3) Catalase llpl3 pINT-800 (Quan et al., 1985) EcoRI-PstI (0.8) (Table II) . In the analysis of the tumour specimens all the polymorphic probes used were able to detect loss or significant reduction (at least 50%) in autoradiographic signal for one of the restriction fragments, indicating LOH in the corresponding locus (Figure 1) . Frequencies of LOH were 47% (9/19 informative) for Ha-rasl, 43% (6/14) for IGF2, 35% (7/20) for Insulin, 50% (2/4) for DlIS12, 25% (4/16) for P Globin, 15% (2/13) and 36% (5/14) for A" Globin and G7 Globin respectively, 40% (6/15) for Calcitonin, 35% (6/17) for DllS17, 29% (7/24) for P-FSH, 26% (6/23) for DllS16 and 25% (6/24) for Catalase. A total of 18 tumour samples from 17 ovarian cancer patients displayed LOH in at least one locus (Table III) 
heterozygous patients with NT, not tested. In fact 11 out of 18 deleted tumour samples (61%) were obtained from patients with liver and/or gallbladder metastasis; on the contrary only three out of the 26 non deleted tumours (11%) were derived from patients with an infiltrated liver and/or gallbladder ( Table I) . The difference between the two groups (deleted and non deleted tumours) was statistically significant (X2 corrected = 9.872, P = 0.002). By considering only liver infiltration, 9/18 and 2/26 were observed to be positive. This difference was also significant (x2 corrected = 8.023, P = 0.005).
Discussion
Deletions on the short arm of chromosome 11 are considered as a common and important event in the development and/or progression of many cancers. Such allelic deletions, in fact, could involve loss of a tumour suppressor gene within the affected region of the chromosome (Marshall, 1991) . Other studies reported I lp deletions in ovarian tumours with nonrandom frequencies of 30-50% (Ehlen & Dubeau, 1990; Lee et al., 1990; Zheng et al., 1991) . In our previous study we found Ha-rasI allelic loss in four out of seven informative cases and, Ha-rasI mutations being absent, we could exclude a loss of competitive effect of mutated versus wild type ras allele (Viel et al., 1991) . In this much wider series of ovarian tumours several other genes located centromeric to Ha-rasI locus on lIp were also analysed in order to determine the extension of the chromosome deletion.
The frequency of Ilp LOH found in our ovarian carcinoma samples (at least 41%) is similar or even higher than those previously reported for Wilms and other tumours (Fearon et al., 1985; Ludwig et al., 1991; Mackay et al., 1988; Reeve et al., 1989) and is likely to reflect somatic events specifically involved in tumourigenesis. Deletion affecting chromosome lp were not so frequent in the study of Sato et al. (24%), but the reason for this apparent discrepancy might be consequent upon the different number and type of the loci tested (Sato et al., 1991) . Furthermore our data indicate the existence of two hot spots of gene deletion on the short arm of chromosome 11, similarly to that described for Wilms tumours (Reeve et al., 1989; Wadey et al., 1990 ) and lung carcinomas (Weston et al., 1989; Ludwig et al., 1991) .
The first hot spot of gene deletion in ovarian carcinomas, mapping on band 1 lpl3 between Dl1IS16 and Catalase loci, corresponds to the chromosome location of the WT-1 gene (Rose et al., 1990) . WT-1 gene encodes a putative transcription factor implicated in nephrogenesis and gonad development (Pelletier et al., 1991c (Wilms tumour, Aniridia, Genitourinary malformation, mental Retardation) and Denys-Drash syndromes (Gessler et al., 1990; Haber et al., 1990; Pelleteir et al., 1991a; Pelletier et al., 1991b) . At present, we cannot state that this growth regulatory gene is implicated in ovarian carcinogenesis. However, its restricted tissue-specific expression in adults (gonads, kidney, uterus, spleen and peritoneal layers between organs) and, in particular, the very high WT-1 expression levels observed in granulosa and epithelial cells of the normal ovary (Pelleteir et al., 1991c) , suggest that loss of a WT-1 allele may contribute to the aetiology of the lIpl3 deleted ovarian tumours.
The second hot spot of gene deletion in ovarian carcinomas, mapping on band llpl5.5 and telomeric to the P Globin gene, corresponds to chromosome location of the putative WT-2, initially associated with the Beckwith Wiedemann syndrome (Koufos et al., 1989) . At present, there is no information about DNA sequences on Ipl15.5 possibly involved in Wilms, ovarian and other tumours. According to other authors (Ehlen & Dubeau, 1990; Lee et al., 1990; Zheng et al., 1991) we found a remarkably high percentage of allelic losses (47%) at the Ha-rasl locus. However, Harasl LOH is unlikely to imply a direct role of such oncogene in ovarian carcinogenesis since genetic alterations were never detected at the retained allele (van't Veer et al., 1988; Viel et al., 1991) . More probably, Ha-rasl LOH marks allelic loss of adjacent genomic sequences functionally involved in ovarian tumourigenesis. We are currently analysing, in ovarian carcinomas, the role of the gene encoding insulin like-growth factor II (IGF2), which maps close to Ha-rasl and whose expression is altered in Wilms, rhabdomyosarcomas and hepatoblastomas, malignancies also characterised by IIpI5.5 LOH (Scott et al., 1985) . We do not know if the two putative tumour suppressor genes have similar functions in ovarian carcinogenesis. However, their independent deletion in some tumours of our series, as well as in Wilms tumours (Wadey et al., 1990) , suggests that they can contribute independently to the stepwise development of the fully malignant phenotype. Moreover, the concomitant deletion of both genomic regions in some tumours (Henry et al., 1989) , such as tumours 8-RR, 1 3-ZE and 40-PL with two separated areas of deletion, indicates that the two genes may act synergistically. At present, our analysis does not allow us to establish if the two lp deletions in 8-RR, 13-ZE and 40-PL, but also in the other ovarian tumours with deletions extending apparently uninterrupted from lIpl3 to lIpl5.5, occurred on one chromosome or were derived from alternate deletions involving both paternal and maternal chromosomes. In any case, the high frequency of the concomitant lipl3 and lIpl5.5 deletions suggests the importance of this event in ovarian carcinogenesis.
Correlations with clinicopathological parameters demonstrated that in the group of patients with the loss of lIp alleles in their tumour (18 cases), 61% had a diagnosis of liver and/or gallbladder metastasis, whereas this infiltration was present in only 11% of the patients with lp non deleted tumours. The statistically significant association we observed between liver metastasis and loss of lip polymorphic loci, leads us to hypothesise that in ovarian cancer the presumed _l I lp oncosuppressor genes are involved in tumour progression rather than initiation. The biological significance of this correlation could be interpreted with the acquisition of a particular metastatic phenotype (ability to colonise the liver) by the tumour cells which lose I lp genes. According to this hypothesis patient RA, free of metastatic liver invasion, did not display such allelic losses in none of the two peritoneal tumour samples (16-RA and 17-RA); patient RR displayed I lp LOH late in the tumour evolution (tumour 8-RR), when a liver metastasis was diagnosed; finally patient ZE developed lip LOH in her primary tumour (13-ZE) before clinical diagnosis of hepatic metastasis. These observations bring into question the possibility of a predictive role of lIp LOH analysis in the identification of patients at high risk to develop liver metastasis. More extensive studies, however, are required to reach a firm conclusion on this point and we are planning to extend this study to a larger number of new selected cases to define the reliability of this molecular marker.
